In a report released yesterday, Joseph Schwartz from Leerink Partners maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), ...

William Blair increased their FY2024 earnings estimates for PTC Therapeutics in a report issued on Monday, January 13th.

Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for PTC Therapeutics in a report ...

Cantor Fitzgerald lowered the firm’s price target on PTC Therapeutics (PTCT) to $76 from $80 and keeps an Overweight rating on the shares. The ...

PTC Therapeutics stock launched north of a profit-taking zone Monday after Novartis agreed to pay up to $2.9 billion to license its Huntington's treatment. Please watch the video at Investors.com ...

PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet its primary and secondary efficacy endpoints.The biotech company said ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up ...

WARREN, N.J., Dec. 17, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 13, 2024, the company approved non-statutory stock options to purchase an aggregate ...

WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing ...